膿痂疹治療の世界市場2019-2023

【英語タイトル】Global Impetigo Treatment Market 2019-2023

Technavioが出版した調査資料(IRTNTR30257)・商品コード:IRTNTR30257
・発行会社(調査会社):Technavio
・発行日:2018年11月28日
・ページ数:104
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、膿痂疹治療の世界市場について調査・分析し、市場概要、市場環境、膿痂疹治療市場規模、製品別(局所用、経口)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・膿痂疹治療の世界市場概要
・膿痂疹治療の世界市場環境
・膿痂疹治療の世界市場動向
・膿痂疹治療の世界市場規模
・膿痂疹治療の世界市場:業界構造分析
・膿痂疹治療の世界市場:製品別(局所用、経口)
・膿痂疹治療の世界市場:地域別市場規模・分析
・膿痂疹治療の北米市場規模・予測
・膿痂疹治療のヨーロッパ・中東・アフリカ市場規模・予測
・膿痂疹治療のアジア太平洋市場規模・予測
・膿痂疹治療の主要国分析
・膿痂疹治療の世界市場:意思決定フレームワーク
・膿痂疹治療の世界市場:成長要因、課題
・膿痂疹治療の世界市場:競争環境
・膿痂疹治療の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Cutanea Life Sciences、GlaxoSmithKline、LEO Pharma、Medimetriks Pharmaceuticalsなどです。
【レポートの概要】

About this market
The evolving resistance of microorganisms is likely to push growth in the market. There has been evolving resistance owing to the frequent usage of oral antibiotics. Hence manufacturers are developing more effective antibiotics to treat skin infections. Technavio’s analysts have predicted that the impetigo treatment market will register a CAGR of about 7% by 2023.
Market Overview
Low cost of treatment
Impetigo is a common, highly contagious bacterial skin infection. However, the infection can be treated easily without spending much.
Side effects of drugs
Impetigo is a bacterial infection of the skin which is treated with topical antibiotics or oral drugs. However, few side effects of these drugs may pose a challenge to the market.
For the detailed list of factors that will drive and challenge the growth of the impetigo treatment market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Cutanea Life Sciences and GlaxoSmithKline the competitive environment is quite intense. Factors such as the low cost of treatment and the low cost of treatment, will provide considerable growth opportunities to impetigo treatment manufactures. Cutanea Life Sciences, GlaxoSmithKline, LEO Pharma, and Medimetriks Pharmaceuticals are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.’

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
• Pipeline analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Topical – Market size and forecast 2018-2023
• Oral – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: SEGMENTATION BY DRUG CLASS
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 13: MARKET TRENDS
• Market trends
PART 14: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 15: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Cutanea Life Sciences
• GlaxoSmithKline
• LEO Pharma
• Medimetriks Pharmaceuticals
PART 16: APPENDIX
• Research methodology
• List of abbreviations
PART 17: EXPLORE TECHNAVIO


Exhibit 01: Global dermatological drugs market
Exhibit 02: Segments of global dermatological drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Product – Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Topical – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Topical – Year-over-year growth 2019-2023 (%)
Exhibit 21: Oral – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Oral – Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 29: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 31: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 33: Key leading countries
Exhibit 34: Market opportunity
Exhibit 35: Impact of drivers and challenges
Exhibit 36: Vendor landscape
Exhibit 37: Landscape disruption
Exhibit 38: Vendors covered
Exhibit 39: Vendor classification
Exhibit 40: Market positioning of vendors
Exhibit 41: Cutanea Life Sciences – Vendor overview
Exhibit 42: Cutanea Life Sciences – Organizational developments
Exhibit 43: Cutanea Life Sciences – Key offerings
Exhibit 44: GlaxoSmithKline – Vendor overview
Exhibit 45: GlaxoSmithKline – Business segments
Exhibit 46: GlaxoSmithKline – Organizational developments
Exhibit 47: GlaxoSmithKline – Geographic focus
Exhibit 48: GlaxoSmithKline – Segment focus
Exhibit 49: GlaxoSmithKline – Key offerings
Exhibit 50: LEO Pharma – Vendor overview
Exhibit 51: LEO Pharma – Organizational developments
Exhibit 52: LEO Pharma – Geographic focus
Exhibit 53: LEO Pharma – Key offerings
Exhibit 54: Medimetriks Pharmaceuticals – Vendor overview
Exhibit 55: Medimetriks Pharmaceuticals – Organizational developments
Exhibit 56: Medimetriks Pharmaceuticals – Key offerings



【掲載企業】

Cutanea Life Sciences、GlaxoSmithKline、LEO Pharma、Medimetriks Pharmaceuticals

★調査レポート[膿痂疹治療の世界市場2019-2023] (コード:IRTNTR30257)販売に関する免責事項を必ずご確認ください。
★調査レポート[膿痂疹治療の世界市場2019-2023]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆